CHI3L1 and cardiovascular disorder: Whether this indicates that these controls indeed had an ongoing subclinical inflammatory process is possible and raises the possibility that PTX3 might be a potential future risk biomarker in diseases characterized by subclinical inflammation as cardiovascular diseases even in individuals with no apparent symptoms in line with what has been suggested for CRP, suPAR and YKL-40 [23]–[25].